Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome (NCT07538583)
A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Who can join: Review the eligibility criteria below.
Location: Center for Dermatology Clinical Research — Fremont, California
Age range: 4 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Center for Dermatology Clinical Research — Fremont, California
- Yale University School of Medicine — New Haven, Connecticut
- Dawes Fretzin Clinical Reseacrh Group — Indianapolis, Indiana
- Beacon Clinical Research — Quincy, Massachusetts
- Texas Dermatology and Laser Specialists — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (858) 571-1800
Email: clinicalresearch@therapeuticsinc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Netherton Syndrome
- Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome — San Diego, California
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome — San Diego, California
- Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome — Chicago, Illinois
- A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 — Palo Alto, California
Explore by condition: All Netherton Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.